McKesson, Stockholders Reach $175M Deal In Opioid Suit
Law360 (January 23, 2020, 9:30 PM EST) -- Stockholders suing pharmaceutical distributor McKesson Corp. told a Delaware Chancery Court judge Thursday they had reached a $175 million settlement to resolve claims the company’s board failed in its oversight of opioid sales even after incurring millions in fines for previous compliance failures.
The stockholders sent a letter to Chancery Court Judge Sam Glasscock III, saying they had submitted the deal to a California federal court for preliminary approval, with a hearing on final approval set for April 21. The deal would cover all the parties to both the Delaware and California suits, the stockholders said.
It’s not yet clear whether...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!